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Abstract
Background:  Key molecules involved in notochord differentiation and function have been
identified through genetic analysis in zebrafish and mice, but MEK1 and 2 have so far not been
implicated in this process due to early lethality (Mek1-/-) and functional redundancy (Mek2-/-) in the
knockout animals.
Results: Here, we reveal a potential role for Mek1/2 during notochord development by using the
small molecule Mek1/2 inhibitor U0126 which blocks phosphorylation of the Mek1/2 target gene
Erk1/2 in vivo. Applying the inhibitor from early gastrulation until the 18-somite stage produces a
specific and consistent phenotype with lack of dark pigmentation, shorter tail and an abnormal,
undulated notochord. Using morphological analysis, in situ hybridization, immunhistochemistry,
TUNEL staining and electron microscopy, we demonstrate that in treated embryos the
chordamesoderm to notochord transition is disrupted and identify disorganization in the medial
layer of the perinotochordal basement mebrane as the probable cause of the undulations and
bulges in the notochord. We also examined and excluded FGF as the upstream signal during this
process.
Conclusion: Using the small chemical U0126, we have established a novel link between MAPK-
signaling and notochord differentiation. Our phenotypic analysis suggests a potential connection
between the MAPK-pathway, the COPI-mediated intracellular transport and/or the copper-
dependent posttranslational regulatory processes during notochord differentiation.
Background
One of the greatest challenges in developmental biology
is to bridge the gap between cell biology and experimental
developmental genetics (ie. to link the function of a pro-
tein at the level of cell and organism). In order to achieve
this, one has to use the methods, tools and results offered
by other research fields. For developmental biologists,
one possibility is to start in vivo testing of small molecules
identified in chemical array experiments once their specif-
icity is satisfactorily established in biochemical and cell
culture assays. The use of such specific chemicals could
identify functions of a protein obscured by early lethality
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in knockout or transgenic animals or by functional redun-
dancy due to the activity of paralogous genes. This
approach is also attractive as small molecules/drugs can
be applied and withdrawn at will, providing an alternative
for expensive and time-consuming transgenic experi-
ments. The use of signaling pathway modifying chemicals
is particularly feasible in classic genetic model organisms
such as Drosophila and zebrafish, due to their relative
cheapness and the availability of large numbers of exter-
nally and quickly developing embryos which allows rapid
and parallel testing of various concentrations and applica-
tion time points [1]. Recently several chemicals have been
tested which are now widely used as inhibitors of certain
pathways in developmental studies (eg. SU5402-fibrob-
last growth factor (FGF) signaling pathway, cyclopamine-
hedgehog (Hh) signaling pathway, SB-431542-TGFβ sign-
aling pathway [2-6]). Moreover, large-scale small mole-
cule screens have been carried out to identify potential
drugs for various diseases [7,8].
The compound U0126 (1,4-diamino-2,3-dicyano-1,4-bis
[2-aminophenylthio]butadiene) was originally identified
as an inhibitor of AP-1 transactivation in a cell-based
reporter assay [9]. This inhibition turned out to be due to
direct and specific inhibition of the mitogen-activated
protein kinase kinase (MAPKK) family members, MEK1
and MEK2. The MAPK pathway is one of the most thor-
oughly characterized intracellular signaling pathways
transmitting extracellular signals (eg. growth, stress or dif-
ferentiation factors) [10-12]. It has been implicated in var-
ious processes including cell proliferation, survival and
differentiation [13] as well as in development [14]. Cur-
rently there are 6 known MAPK signaling pathways:
(ERK1/2, ERK3/4, ERK5, ERK7/8, JNK1/2/3 and p38/
ERK6) and although in vitro studies have described bio-
chemical characteristics of these cascades in detail, their
diverse (or redundant) roles during vertebrate develop-
ment have only recently come under scrutiny [15-17].
Inhibitory activity of U0126 is selective for MEK1 and
MEK2, and shows very little, if any, effect on the kinase
activities of other protein kinases like c-Abl, Raf, MEKK,
ERK, JNK, MKK-3, MKK-4/SEK, MKK-6, Cdk2, or Cdk4
[18]. Since its description, more than 1500 papers have
used this inhibitor, confirming its specificity in vitro.
Results of ex vivo tissue explant experiments have impli-
cated the involvement of MEKs in a wide range of devel-
opmental processes including angiogenesis [19,20], renal
tubulogenesis [21,22], somitic segmentation [23], lens
differentiation [24] as well as guidance and segregation of
retinal afferents during mammalian visual system devel-
opment [25,26]. In vivo testing of U0126 has been carried
out in ascidian species (Halocynthia roretzi and Ciona
intestinalis), where U0126 treatment blocked differentia-
tion of mesenchyme, secondary muscle and neural tissues
and formation of the notochord (NC) [27-29].
The NC serves as the most important skeletal structure in
lower chordates and plays an essential role in vertebral
column development in vertebrates. Its equally important
function is to provide critical signaling molecules to
neighbouring tissues (eg. neurectoderm, paraxial meso-
derm), directing their differentiation [30]. The mature NC
develops from the chordamesoderm, a derivative of dor-
sal mesoderm, and is ultimately incorporated into the
forming vertebrae as the nucleus pulposus.
Here we report the analysis of zebrafish embryos treated
with the MEK1/2 inhibitor U0126 which causes an almost
100% penetrant, dose-dependent and reproducible phe-
notype consisting of short trunk and tail, lack of dark pig-
mentation, and abnormal NC development. Time-course
and washout experiments revealed that the treatment has
to be applied within a strict time window from the begin-
ning of gastrulation until 16–18-somite stage (around 18
hours post-fertilization, hpf) and the strength of the phe-
notype correlates with the level of Erk phosphorylation
observed in the embryos. The NCs of U0126 treated
embryos develop undulations and form multi cell-layer
lumps instead of the single „stack-of-coins" structure
observed in wild type siblings. Electron microscopy
revealed defects in the multilayered structure of the peri-
notochordal basement membrane (PNBM) which sup-
ports NC cells against their own high internal hydrostatic
pressure. We show that the shorter tail of the treated
embryos is due to an increase in apoptosis and not to a
decrease in number of mitotic cells. Gene expression anal-
ysis showed that U0126 affects the chordamesoderm to
mature NC transition step. Surprisingly, ventral fates in
the neural tube are not affected while development of the
dorsal aorta and intersomitic vessels is severely disturbed.
U0126-treated embryos do not show any significant sim-
ilarity to those treated with the FGF-signaling inhibitor
SU5402 which suggests that an alternative pathway is
required to activate MEK during NC development. We
also examined possible links to pathways whose inhibi-
tion in different mutants produce a very similar pheno-
type including COPI-mediated intracellular transport and
the copper-transporter Atp7a. We conclude that MEK1/2
inhibition did not decrease the expression of any of the
potential genes examined, nevertheless, interactions
between these processes and MAPK1/2 signaling may exist
at the protein level.
Results
U0126 treatment during gastrulation causes notochord 
and pigmentation defects in zebrafish
The specificity of U0126 as a MEK1/2 inhibitor has
already been established by many studies both in vitro
[31] and in vivo [32] including one analysis in zebrafish
[33]. Consistent with those analyses, treatment of
zebrafish embryos with U0126 from early gastrulation ledBMC Developmental Biology 2008, 8:42 http://www.biomedcentral.com/1471-213X/8/42
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U0126 application during a specific time-window decreases ERK phosphorylation specifically Figure 1
U0126 application during a specific time-window decreases ERK phosphorylation specifically. A: Diphospho-Erk staining in the trunk of wt 24 
hpf embryos.B: U0126 eliminates ERK1/2 phosphorylation (green) in the trunk and tail of 24 hpf zebrafish embryos. Notice that U0126-treated embryos 
have been overexposed (can be judged by the autofluorescence of the yolk sac extension) and still fail to show specific staining. C: U0124 does not elimi-
nate the p-Erk staining. D: PD98059 also does not eliminate p-Erk staining when given just below the level of lethal toxicity (25 μM). E: Somewhat weaker 
but still significant p-Erk staining in embryos treated with U0126 starting at 10 hpf. F: Western-blot analysis demonstrated a slight but incomplete reduc-
tion in pErk1/2 levels in 10-somite embryos.G: Stage and dose-dependency of U0126 application. There is a dramatic drop in the percentage of affected 
embryos when treatment is applied after epiboly is completed. H: Washout experiments reveal the necessity of U0126 to be present until at least the 18 
somite stage to produce the full phenotype.BMC Developmental Biology 2008, 8:42 http://www.biomedcentral.com/1471-213X/8/42
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to complete abrogation of the phosphorylation of Erk1/2,
the downstream target of Mek1/2 (Fig. 1/A,B). This was
not the case when the embryos were treated under the
same the same conditions with U0124, a small molecule
with a slightly changed composition which results in loss
of MEK1/2 inhibitory capacity, supporting the specificity
of the U0126 effect (Fig. 1/C). PD98059, also used as a
MEK1/2 inhibitor in vitro [34], caused no phenotype
whatsoever at 20 μM and resulted in 100% lethality at 30
μM concentration. PD98059 has been shown to be 100-
fold less potent than U0126 in vitro [9]. This suggests that
its lethality at such a low concentration was due to non-
specific causes, preventing us from analysing its effect as a
MEK1/2 inhibitor. Indeed, embryos treated with sublethal
20 and 25 μM PD98059 (Fig. 1/D; panel is 25 μM) had
normal phospho-ERK1/2 staining, suggesting normal
MEK activity.
Next we tested the inhibitor at several concentrations and
at several starting time-points (Fig. 1/G). The lowest effec-
tive concentration that still gave the strongest observed
phenotype (detailed below) was 100 μM, so that was used
in all subsequent experiments. Higher concentrations of
the inhibitor (up to 1 mM; U0126 precipitates beyond 1
mM) did not produce a stronger or different effect, sug-
gesting low non-specific toxicity of U0126. The induced
phenotype was very distinct and reproducible, while
DMSO sham controls never showed any defects. In order
to achieve maximum effect, it was necessary to apply the
inhibitor during early gastrulation (Fig. 1/G). Under these
conditions (100 μM applied at early gastrulation), the effi-
cacy rate of the experiments never fell below 90% in sev-
eral thousand embryos. When the drug was added at later
stages (starting 85–90% epiboly or afterwards) the effect
on Erk1/2 phosphorylation was proportionally weaker
(Fig. 1/E), appeared later and affected only the posterior
part of the NC. Treatment with lower concentrations of
U0126 from early gastrulation also produced a weaker
phenotype and reduced the number of affected embryos
(Fig. 1/G).
To examine whether slow penetration of U0126 into the
embryo might explain why there is such a delay between
treatment and derived effect we stained embryos at 10
somite stage with pERK1/2 (as above). As suspected, there
was no decrease in pErk1/2 signal (data not shown) sug-
gesting that the drug did not penetrate quickly. To exam-
ine this with greater sensitivity we carried out Western-
blot analysis using the pERK1/2 antibody on lysates of the
U0126 treated and DMSO control embryos at the same 10
somite stage. This revealed a decrease in pErk1/2 after
U0126 treatment (Fig. 1/F). Nevertheless, there was still
some pErk1/2 present indicating slow penetration and/or
effect of the drug in zebrafish embryos.
To identify the time point when U0126 has to be present
to induce the NC phenotype, we also carried out washout
experiments at different stages of development. These
demonstrated that U0126 has to be continously present
from the onset of gastrulation until at least 17–18 somite
stage to achieve full penetrance of the phenotype (Fig. 1/
H). When washed out earlier than that, only the anterior
part of the NC was affected. This result, combined with
the late application data (Fig. 1/G) suggests the existence
of a time-window during which the NC cells are sensitive
to U0126. This sensitivity window moves in an A-P direc-
tion as the NC differentiates. For subsequent experiments
we routinely started treating the embryos at the onset of
gastrulation and kept them in the inhibitor until the
required fixation time-point.
U0126 incubation produced a phenotype with two major
characteristics. First, the embryos lacked all accumula-
tions of the dark pigment melanin and remained com-
pletely translucent provided that they were kept
continuosly in the inhibitor (Compare Fig. 2/G–I with
Fig. 2/J–L). If taken out from the U0126 solution after 24
hpf, dark pigmentation slowly recovered although it never
became quite as strong as it was in control embryos. Fol-
lowing this recovery, the pattern of pigmentation was
identical to the untreated controls', albeit not as strong. A
likely explanation for the pigmentation effect of U0126
was provided recently by Gelfand and colleagues who
showed that U0126 treatment inhibits melanosome
transportation within fully differentiated melanophore
cells in vitro [35].
The second major defect consisted of severe morphologi-
cal abnormalities in the trunk of U0126 treated embryos.
The first sign of this was a ventral bending of the tail of
treated embryos at around 20 hpf. By 24 hpf the the NC
was severely affected (Fig. 2/A,B,D,E), while other parts of
the treated embryo (brain, somites) appeared morpholog-
ically normal (Fig. 2/C,F). By 48 hpf the tail was signifi-
cantly shorter (compare Fig. 2/G,J), the somites had a
straight shape instead of the normal chevron (V) shape
(see also Fig. 3./E,F), and the NC developed very severe
kinks, thickenings and undulations, sometimes even
knot-like features (Fig. 2/H,K). At this stage the structure
of the brain still appeared normal (Fig. 2/I,L), but soon
afterwards a necrotic process was initiated here which
spread over the embryo resulting in death during the fol-
lowing couple of days.
U0126 does not affect early dorso-ventral patterning and 
convergent-extension movements during gastrulation
The previous experiments revealed that in order to achieve
the maximum NC phenotype, inhibitor treatment must
commence at the start of gastrulation, so we examined
whether patterning processes occuring at this time areBMC Developmental Biology 2008, 8:42 http://www.biomedcentral.com/1471-213X/8/42
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affected by U0126. FGF signaling, which transduces its
signal through the MAPK pathway, plays a significant role
in zebrafish dorso-ventral (D-V) and anterior-posterior
(A-P) patterning and tail formation [36-39]. Moreover,
embryos of mildly dorsalized zebrafish mutants (eg. swirl,
somitabun, lost-a-fin, minifin, snailhouse; [40,41]) have a
U0126 produces a specific and consistent phenotype affecting pigmentation and notochord development Figure 2
U0126 produces a specific and consistent phenotype affecting pigmentation and notochord development. Phe-
notype of wild type and U0126-treated embryos at 24 hpf. (A-F) and at 48 hpf (G-L). There is a total lack of pigmentation 
including in the RPE in the eye (compare panels I and L), twists and undulations in the NC are already evident at 24 hpf. (D, E) 
and the trunk and tail of treated embryos is shortened at 48 hpf (compare panels G and J). The large yolk sac in 48 hpf 
embryos indicates that circulation is not established properly to carry away its content (see also later in Fig. 5) Panels A-C, G-
I: wild type embryos. Panels D-F, J-L: U0126-treated embryos.BMC Developmental Biology 2008, 8:42 http://www.biomedcentral.com/1471-213X/8/42
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Early processes are not affected by U0126 with the exception of apoptosis Figure 3
Early processes are not affected by U0126 with the exception of apoptosis. A-D: Expression the dorsal marker gsc (A, B,), and the ventral mes-
odermal marker gene eve1 (D, E) is not changed in 7 hpf. U0126-treated animals. As treated and wt animals could not be separated at this stage, a large 
number of embryos were treated and some of them were raised till 24 hpf. to make sure the drug was effective. E, F: Narrower, straighter somites in 
U0126-treated embryos as demonstrated by the reduced distance between the motoneurons (1 motoneuron/somite) stained with α-Acetylated-Tubulin 
antibody. G, H: Lateral mesoderm marker gene pax 2.1 (purple) and the somitic mesodermal marker gene myoD (red) do not show altered expression in 
dorsal view of flat-mounted 9-somite stage embryos. Expression of genes involved in tail development is not changed after U0126-treatment. I-L:flh. M, N: 
cdx1. O.P: eve1. Q, R: fgf8. S, T: Examples of shh-GFP and α-phosphorylated Histone3 double antibody staining used to count mitotic cells in the NC. U-
X: Examples of TUNEL stainings of 24 hpf (U, V) and 48 hpf (W, X) wt and U0126-treated embryos (inset in panel X shows larger magnification and see 
these cells also in Fig. 6/F marked with yellow arrows). Y': The average numbers of phosphorylated Histone3 (pH3) positive cells in the anterior and pos-
terior trunk and tail do not differ between wt and U0126-treated embryos. Average numbers of TUNEL positive cells in whole embryos (Y") and noto-
chord-only (Y"') at 20 somites and 24 hpf demonstrate a significant increase in U0126-treated embryos at 24 hpf (p = 0.0087 unpaired t-test with welch's 
correction, 24 hpf values). Note that there is no change in apoptosis within the NC. Panels A, C, E, G, I, K, M, O, Q, S, U, W: wild type embryos. Panels 
B, D, F, H, J, L, N, P, R, T, V, X: U0126-treated embryos. Panels A, D animal pole view, dorsal to the right.BMC Developmental Biology 2008, 8:42 http://www.biomedcentral.com/1471-213X/8/42
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shift in mesendodermal fate, producing more noto-
chordal tissue and less, or no, ventral mesoderm which
could be the reason for the undulating NC found in
U0126-treated embryos. To examine this possibility, we
checked distribution of gsc and eve1, a dorsal and ventral
mesoderm marker, respectively. Neither of these (Fig. 3/
A–D), nor similar markers examined (data not shown)
had an altered expression pattern, indicating that D-V
specification is not disturbed by U0126 treatment.
Another process that may be affected by U0126 treatment
is convergent-extension (C-E). C-E defects produce a short
trunk and compressed, straight somites similar to those
observed in U0126-treated embryos (Fig. 3/E,F) [42,43].
Moreover, a C-E mutant knypek  encodes the zebrafish
homologue of Drosophila glypican: a heparan-sulfate
proteoglycan mediator of FGF signaling [44]. However, 8-
somite stage U0126-treated embryos showed no defects in
the expression of somitic and lateral mesodermal marker
genes (myoD  and  pax2.1  respectively), indicating no
delays in C-E movements of mesodermal cells (Fig. 3/
G,H).
Alternatively, the short tail phenotype could also be the
result of a defect in tail elongation. However, no change
was observed in the expression of a number of genes
known to be involved in this process, such as flh, fgf8, eve1
or cdx1 (Fig. 3/I–R).
We next checked whether an increase in cell division in
the NC could be responsible for the generation of undula-
tions in this stucture. To follow changes in mitosis, we
counted dividing cells in the NC of wild type and treated
embryos stained for the mitotic marker phospho-histone3
(which labels cells that are in the M phase at the time of
fixation). To ensure that we only counted notochordal
cells, we used shh-GFP embryos [45] as a counterstain and
only double stained cells were counted (arrows in Fig. 3/
S,T,Y'). This revealed no differences in the number of M
phase cells in the NC at 24 hpf in control versus U0126-
treated embryos (Fig. 3/Y'; wt: 37 α-H3 positive NC cells/
7 embryos; U0126-treated: 35 positive NC cells/7
embryos). To assess any changes in the A-P distribution of
mitoses, cells between the posterior tip of the tail and the
end of the yolk tube extension were also counted sepa-
rately. The distribution of mitotic cells also did not change
in treated embryos (11 cells/7 embryos in both cases).
Thus, changes in cell division rates in the NC are unlikely
to be responsible for its undulations. U0126 treatments
did, however, increase apoptosis in the tail of treated
embryos, as assessed by TUNEL staining. Since the
number of TUNEL positive cells showed substantial vari-
ability (between 20 and 150 cells/embryo), we carried out
counting on a large number of embryos (24 embryos/
sample). At 20 hpf there was no difference in the number
of apoptotic cells between wild type and treated embryos
(Fig. 3/Y"), but by 24 hpf there was a specific and severe
increase of apoptosis in the tail mesenchyme (Fig. 3/
U–V,Y") of about one-third of the treated embryos. The
increased apoptosis in the tail mesenchyme could explain
the shortness of 48 hpf embryos, and may account, at least
partially, for the undulations of the NC. On the other
hand, we could not detect any increase in apoptosis
within the NC (Fig. 3/Y"'). At 48 hpf apoptosis was also
initiated in the smaller, vacuolated NC cells (Fig. 3/X,
inset; yellow arrows in Fig. 6/F). Apoptosis in the NC
remained restricted to these cells.
U0126 treatment disrupts the chordamesoderm to mature 
notochord transition and proper signaling to surrounding 
tissues
To find the possible molecular consequences of U0126
treatment which led to the NC phenotype, we inspected
the expression pattern of structural and regulatory genes
involved in NC differentiation, most of which also play a
role in tail development. ntl, the zebrafish orthologue of
mouse Brachyury, is involved in NC and tail development
in all vertebrates examined so far [46-50]. In wild type
embryos, ntl is expressed in the NC during its develop-
ment and from 20 hpf its expression progressively decays
in an A-P fashion. Early expression of ntl was absolutely
normal in U0126-treated zebrafish embryos (Fig. 4/A–D).
From 20 hpf onwards however, unlike in untreated sib-
lings, its expression did not decrease, in fact it was main-
tained at high levels (Fig. 4/E–H). This lack of proper
mRNA decay in treated embryos also characterized expres-
sion of several other genes important in NC development
and tail formation including ehh and shh (but not twhh)
from the Hh family of signaling molecules, the structural
protein col2α1 and its specific chaperone hsp47 (Fig. 4/
I–P). In contrast, other genes also involved in NC devel-
opment, such as members of type I forkhead transcription
factors (fkd1, fkd4; Fig. 4/Q,R,U,V) as well as tiggy-winkle
hedgehog (twhh; Fig. 5/I,J), spondin2 and mindin, showed
normal expression dynamics in treated embryos (Fig. 4/
Q–X).
Since expression of many genes belonging to develop-
mentally important signaling pathways were affected by
U0126-treatment, we examined whether differentiation
of surrounding tissues known to require NC-emitted sig-
nals for their development (muscle, neural tube, circula-
tory system) were affected. flk and tie-2 expression, as well
as Fli1-eGFP fluorescence all revealed considerable defects
in circulatory system differentiation (Fig. 5/A–D; data not
shown). Disruptions of flk gene expression were observed
in the dorsal aorta (Fig. 5/D), and we also detected double
sprouting of intersomitic vessel progenitors within the
same somite (Fig. 5/D, red arrow). In most cases, how-
ever, there was no detectable sprouting at all from the pre-BMC Developmental Biology 2008, 8:42 http://www.biomedcentral.com/1471-213X/8/42
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Genes important in notochord differentiation exhibit two types of regulatory pattern during chordamesoderm to mature NC  transition Figure 4
Genes important in notochord differentiation exhibit two types of regulatory pattern during chordamesoderm 
to mature NC transition. A-H: Expression of ntl is normal during early NC development (A-D) in treated embryos but fails 
to get downregulated during the chordamesoderm to mature NC transition step (E-H). (A, B: 7 hpf; C, D: 12 hpf; E-H 24 
hpf.) This pattern of developmental arrest occurs in ehh (I, J), shh (L, K), col2α1 (M, N) and hsp47 (O, P) expression. Q-X: 
mRNA levels of fkd1 (Q, R), fkd4 (S, T), spondin2 (U, V) and mindin (W, X) however decreases normally upon chordameso-
derm to mature NC transition. Notice the unchanged expression of marker genes in the floor plate (M-X) and in the hypo-
chord (O, P, U-X) of U0126-treated embryos. Panels: A, C, E, G, I, K, M, O, Q, S, U, W: wild type. Panels: B, D, F, H, J, L, 
N, P, R, T, V, X: U0126-treated embryos.BMC Developmental Biology 2008, 8:42 http://www.biomedcentral.com/1471-213X/8/42
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cursors, suggesting that development of these vessels
requires NC signals (Fig. 5/D, yellow arrows).
Early muscle differentiation markers showed only very
mild or no defects (eg. myoD Fig. 5/E,F). Also, expression
of the sarcomeric gene α-tropomyosin was not affected at all
(data not shown). The level of expression of the slow mus-
cle pioneer cell marker eng2, however, was significantly
increased. Instead of its normal staining pattern, where
only the anteriormost 2–3 cells in each somite at the som-
itic midline expresses eng2  mRNA, in U0126-treated
embryos its expression spanned the entire myotome pro-
ducing a continuous band along the D-V midline (Fig. 5/
G,H).
The neural tube lies just dorsal to the NC and proper dif-
ferentiation of its ventral part (floor plate, motoneurons)
is dependent on notochordal signals. Despite this, and
much to our surprise, the floor plate developed normally
in U0126-treated embryos as judged both by its morphol-
ogy (Fig. 6/A–D) and by the normal expression of shh,
twhh, col2α1, fkd1, fkd,4, spondin2 and mindin genes (Fig.
5/I,J and Fig. 4/M,N,Q–X). Moreover, ventral motoneu-
rons marked by isl-1 also differentiated properly (both in
numbers as well as in position) from neural progenitors
(Fig. 5/K,L).
U0126 treatment induces changes in the actin based 
cytoskeleton and in the structure of the perinotochordal 
basement membrane
To investigate the NC morphology of treated embryos in
more detail, we used the lipophilic vital dye Bodipy cera-
mide, which remains extracellular and outlines the bor-
ders of living cells. Staining of 24 hpf control embryos
revealed a single row of cells in the NC arranged in a
„stack-of-coins" shape (Fig. 6/A). At this age approxi-
Not all tissues receiving notochord-emitted signals are affected by U0126 treatment Figure 5
Not all tissues receiving notochord-emitted signals are affected by U0126 treatment. A-D: flk-1 expression reveals 
defects in dorsal aorta differentiation (green arrow in panel D) and in the sprouting of intersomitic vessels. Notice that both 
lack of sprouting (yellow arrows) and double sprouting (red arrow) occurs in U0126-treated embryos (D). Expression of the 
early muscle differentiation marker myoD is normal in treated embryos (E, F) but the muscle pioneer cell marker eng2 is 
upregulated (G, H). The floor plate of the neural tube differentiates normally (I, J and also Fig. 4/M–X). Isl-1 expression shows 
that the sensory Rohon-Beard neurons and motoneurons both develop properly in treated embryos (K, L)BMC Developmental Biology 2008, 8:42 http://www.biomedcentral.com/1471-213X/8/42
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mately every fourth or fifth cell already showed signs of
vacuolation, which is the first visible morphological
change in the chordamesoderm to NC differentiation
process. In wild type embryos the NC cells were also still
attached to the PNBM very evenly. In the NC of U0126-
treated embryos this even distribution of cells was broken
at several places, with 4–5 NC cells adhering to the PNBM
at the same spot (See red arrow in Fig. 6/B). Such focused
adhesion probably creates mechanical tension causing the
NC to bend towards the adhesion point and might
become an initiator during subsequent kinking/bending
of the NC. The appearance of these structures suggested
Defects in the cellular organization of the notochord and PNBM structure of U0126-treated embryos Figure 6
Defects in the cellular organization of the notochord and PNBM structure of U0126-treated embryos. In 24 hpf. 
U0126-treated embryos notochordal cells adhere to the sheath at preferential focal points which results in the bending of the 
NC (red arrow in panel B). Phalloidin stainings reveal smaller amount of fibrillar actin present between NC cells but not in the 
overlying neural tube. Notice the large vacuolar cells and the periferial positioning of nuclei in U0126-treated embryos (panels 
C, D). By 48 hpf. the NC of U0126-treated embryos with milder phenotypes contains smaller rounded cells which become 
apoptotic (yellow arrows in panel F and see also in Fig. 3/X). Embryos with stronger phenotypes have large bulges protruding 
where the flat sheath cells surrounding the large vacuolated cells are missing (see blue arrows in panel E for normal sheath 
cells and in panel H marking the last sheath cells surrounding the bulge; red arrows mark the region devoid of sheath cells). 
Laminin expression and ultrastructure of the inner layer of the PNBM (marked with blue arrowheads) composed mainly of 
laminins are normal in NC treated embryos as demonstrated by whole-mount immunhistochemistry (I, J) and TEM pictures 
(K, L). The middle (green bracket) and outer (yellow bracket) layers of the PNBM composed mainly of circumferential and lon-
gitudinal collagen fibers respectively show decreased length and/or disorganization in the orientation of fibers (K, L). Panels A, 
C, E, G, I, K: wild type embryos. Panels B, D, F, H, J, L: U0126-treated embryos.BMC Developmental Biology 2008, 8:42 http://www.biomedcentral.com/1471-213X/8/42
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that there might be cell adhesion or/and cytoskeletal
defects involved in the generation of the phenotype, so we
next examined the distribution of fibrillar actin (F-actin)
via fluorescent phalloidin staining (green in Fig. 6/C,D),
with the nuclei being counterstained by Sytox dye (red).
In the medial part of the NC of U0126-treated embryos
the phalloidin staining appeared significantly weaker
indicating that a lower level of F-actin was present (Fig. 6/
D). There was also a change in the appearance and rear-
rangement of notochordal cells with smaller cuboidal
cells lying ventrally along the NC sheath (Fig. 6/D, blue
arrows). Due to this, the large vacuolated cells were not
connected to the sheath directly on the ventral side. At the
points of NC breaks (or severe bends) these smaller cells
intruded into medial parts of the NC (see yellow arrows in
Fig. 6/D).
At 48 hpf the wild type NC contained large vacuolated
cells with 2–3 similar size cells lying side by side (Fig. 6/
E), and smaller flat epithelial-like sheath cells towards the
edge, in close contact with the PNBM (Fig. 6/E, blue
arrows). In U0126-treated embryos with a milder pheno-
type a large number of significantly smaller rounded cells
with a vacuolated appearance were observed (Fig. 6/F, yel-
low arrows). It is not clear whether these cells are formed
from the flat sheet cells secondarily or whether they are
normal vacuolated cells that are simply smaller. In more
severely affected U0126-treated embryos (Fig. 6/G,H), the
flat sheath cells were not present continously along the
NC and where they were missing, large bulges appeared in
the NC consisting of large vacuolated cells (last sheath
cells are marked with blue arrows on both sides of the
bulge in the NC in Fig. 6/H). It is likely that the sheath
cells, together with the PNBM, keep the normal shape of
the NC by resisting the high internal hydrostatic pressure
of vacuolated cells. The absence of the sheath cells in
U0126 treated embryos may account for the formation of
the large bulges in the NC.
As the observed phenotype resembles zebrafish laminin
mutants [51,52], we next checked the presence and distri-
bution of laminin protein around the NC in U0126-
treated embryos by whole-mount immunhistochemistry
(Fig. 6/I–J.). Laminin is expressed normally in treated
embryos, suggesting that U0126 affects events occuring
downstream or in parallel with laminin in NC differenti-
ation. This was also supported by ultrastructural evidence
from transmission electron microscopic (TEM) sections
which showed that in 48 hpf embryos the laminin-based
inner layer of the PNBM was not affected by U0126 treat-
ment (Fig. 6/K,L, blue arrowheads). The medial (green
bracket) and outer layers (yellow bracket) composed
mostly of longitudinally and perpendicularly oriented
crosslinked collagen fibres (mainly type IV) however
showed some disorganization in U0126-treated embryos
(Fig. 6/K,L). This was particularly evident in areas where
the profile of the NC was 'kinked'. In these regions of the
sheath the inner layer of collagen filaments was thinner
and contained shorter collagen fibrils. These 'shorter'
fibrils may be truly shorter or may appear shorter in the
ultrathin sections because their orientation is more longi-
tudinal rather than circumferential to the NC. Either way,
these observations suggest some disorganization in the
collagen layers.
In summary, we can conclude that most probably a com-
bination of the lack of sheath cells and the disorganiation
of the inner layer of the PNBM causes the multiple-cell
wide bulgings in the NC of U0126-treated embryos.
Although it is likely, at this point we can not yet conclude,
whether there is a direct causal relationship between the
missing sheath cells and the PNBM disorganization.
U0126-treated embryos do not resemble FGF pathway-
inhibited embryos
As the FGF pathway is known to transmit its signals via the
MAPK-Erk pathway and it is also involved in trunk and
tail development, we examined whether U0126-treated
embryos resemble those in which the FGF-pathway was
abrogated. We used the FGF pathway inhibitor SU5402,
which has previously been shown to inhibit the FGF path-
way in vivo in zebrafish embryos [38,53]. However, phe-
notypes of embryos treated with SU5402 in the same time
window as U0126lacked any similarity to U0126-treated
embryos. Also, the Fgf-target gene sef (as well as pea3 and
sprouty4; data not shown), which was downregulated in
the somites and tail mesenchyme of SU5402-treated
embryos, was not affected by U0126 treatment (Fig. 7/
A–C). Moreover, the notochordal markers col2a1 and shh
maintained a normal A-P pattern of expression decay in
the NC of SU5402-treated embryos (Fig. 7/D–I). These
data suggest that FGF-signaling is unlikely to be involved
in the activation of MEK in the context of NC differentia-
tion.
The disorganisation found in the NC sheath of U0126-
treated embryos is also a characteristic of zebrafish
mutants which affect COPI-mediated secretion processes
[54] or those with inhibiton of proper copper metabolism
via the copper-transporter Atp7ase [55]. Therefore we
investigated whether expression of the available coatomer
complex and copper-dependent lysyl-oxidase genes are
changed in U0126-treated embryos. The mRNA levels of
some of these genes (lox1, copa) were abnormally main-
tained at high levels in treated embryos (Fig. 7/J,K,N,O) or
decayed normally in other cases (lox5a; Fig. 7/L,M) simi-
larly to what was observed for other notochordal genes.
This suggests that there is no direct regulation of these
genes by the ERK pathway at the transcriptional level butBMC Developmental Biology 2008, 8:42 http://www.biomedcentral.com/1471-213X/8/42
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Inhibition of the FGF pathway by SU5402 does not show any similarities to U0126-treated embryos Figure 7
Inhibition of the FGF pathway by SU5402 does not show any similarities to U0126-treated embryos. A-C: 
Expression of the Fgf-pathway target gene sef is downregulated in SU5402 (C) but not in U0126-treated (B) embryos. D-I: 
Expression of the notochordal marker genes col2a1 (D-F) and shh (G-I) also show different defects in SU5402 and U0126-
treated embryos. J-M: Expression of lox1 (J, K) and lox5b (L-M) is not decreased normally by U0126-treatment. N, O: copa 
mRNA persists and is not downregulated by U0126-treatment.BMC Developmental Biology 2008, 8:42 http://www.biomedcentral.com/1471-213X/8/42
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it is still possible that such a regulatory interaction exists
at the protein level. These studies will have to wait until
specific antibodies are available for all phosphorylated
and unphosphorylated COPI and lysyl-oxidase isoforms.
Discussion
U0126 produces a specific effect during NC development 
in zebrafish
As a welcome side-effect of large scale small molecule
screens, developmental biologists now have access to spe-
cific inhibitors of various signaling pathways which could
provide a simple solution for a temporally controllable
inhibition of developmentally crucial pathways.
MEK1 and MEK2 underscore the usefulness of the chemi-
cal genetics approach. Mek1-/-  mouse embryos die at
E10.5 due to defective development of placental circula-
tion [56], while Mek2-/- animals are viable, fertile and
have no visible phenotype [57]. To reveal possible later
and/or redundant functions of these kinases, we applied
their inhibitor U0126 to live zebrafish embryos. Our
results demonstrate a potential new role for the the MAPK
pathway in NC differentiation.
The specificity of U0126 has been previously demon-
strated in zebrafish in vivo by Peterson and coworkers
[33]. Here we show that U0126 effectively inhibits Erk1/2
phosphorylation in zebrafish embryos when applied from
early gastrulation, and this correlates with the NC defect
detected in our experiments. Treatment of embryos with
U0124, a small molecule similar to U0126 but with a
slightly changed composition, which results in loss of
MEK1/2 inhibitory capacity, did not lead to NC defects.
Accordingly, Erk1/2 phosphorylation was also unaffected
by treatment with this drug. These results suggest that
U0126 has a specific effect during NC differentiation. We
tried a second inhibitor of MEK1/2, PD98059, which is
100-fold less potent than U0126. Unfortunately,
PD98059 treatments were toxic to the embryos at 30 μM,
and at sublethal concentrations (20–25μM) the embryos
did not show any NC phenotype nor any decrease in Erk1/
2 phosphorylation. Given the in vitro data and our results
we have to conclude that the toxicity of this drug did not
allow us to to compare its effect on NC development with
that of U0126.
U0126 disrupts the chordamesoderm to mature NC 
transition process
Our data show that U0126 does not affect early patterning
and morphogenetic events; rather it disrupts a later step
during NC differentiation. This is in contrast to Ascidians
where application of U0126 disrupts an early NC determi-
nation step. In Ciona intestinalis it also decreases expres-
sion of the early NC determination gene Ci-Bra, the
ascidian orthologue of zebrafish ntl which as we demon-
strated does not show any expression defects during early
stages of NC differentiation [29,58]. This suggests that the
U0126 target protein has an earlier function in Ascidian
NC morphogenesis then in zebrafish. Alternatively, the
drug may penetrate more rapidly into the significantly
smaller Ascidian embryos.
In zebrafish, at around 20 hpf chordamesoderm cells start
to differentiate into mature NC and the mRNA levels of
genes required for the early development and signaling
function of the chordamesoderm are downregulated.
Simultaneously, the cells of the differentiating NC begin
to secrete the components of the PNBM, a structure which
will support the NC against its own hydrostatic pressure
and maintain its classic rod-like structure. Our expression
analysis revealed that mRNA levels of important regula-
tory and structural genes are not downregulated in
U0126-treated embryos indicating an arrest of NC differ-
entiation at a stage which approximately corresponds to a
16 hpf embryo. Surprisingly, despite this, the surrounding
tissues are only mildly (or not at all) affected with the
exception of the developing circulatory system, which was
analyzed in detail recently by Peterson and colleagues;
[33], and the slow muscle pioneer cells, which are
increased in number and expand in an A-P direction
within the somitic midline The ventral neural tube (floor
plate and the motoneurons, which also both require
proper Hh-signaling from the NC however, differentiate
properly. This mixed phenotype suggests that some tissues
are not affected because the arrest in NC development
happens only after it has already provided its essential sig-
nals to them (eg. to the neural tube), while others would
still require proper signaling from the NC (eg. circulatory
system, slow muscle pioneer cells). Alternatively, the dif-
ference is due to ability of the surrounding tissues to cope
with the abnormal signals they recieve. Finally, it is possi-
ble that the NC cells are capable of handling the extra
mRNA by translational or posttranslational regulatory
mechanisms. This is supported by the fact that GFP pro-
tein levels in the NC of U0126-treated shh-GFP embryos
appear to be downregulated normally by 48 hpf [data not
shown; [45,59]].
Even though the effects of the U0126 treatment are not
visible until late in somitogenesis, our time-course and
washout experiments revealed that the drug has to be
applied from early gastrulation to achieve a fully pene-
trant phenotype. In addition, the chemical has to be kept
on continously; when treatments start at later stages only
the posterior part of the NC is affected and conversely,
early washout of the chemical produces undulations only
in the more anterior part of the NC. This suggests that
there is a sensitivity window to MEK activity that moves
from anterior to posterior as the NC cells differentiate.BMC Developmental Biology 2008, 8:42 http://www.biomedcentral.com/1471-213X/8/42
Page 14 of 18
(page number not for citation purposes)
FGF signaling is unlikely to be involved in the NC 
differentiation pathway targeted by U0126
We examined FGFs as candidates for the upstream signal
in the U0126-targeted NC differentiation process. FGFs
are known to transmit their signals via the MAPK pathway
[37] and have been implicated in the tail elongation proc-
ess [60]. Unfortunately, they are also involved in D-V pat-
terning, which begins prior to NC differentiation [39]. As
a result of this, in vivo disruption of FGF signaling, using
SU5402, or by using a combination of fgf3 and fgf8 anti-
sense morpholinos (our unpublished data), produced a
severe phenotype which probably masks its later function
during NC differentiation. The fgf8 mutant ace also does
not have an undulating NC, indicating it is not the
upstream signal in this pathway [61]. However, since
U0126 treatments seem to be able to eliminate Erk1/2
phosphorylation, and FGF signalling is transduced by the
activity of these kinases, it seems puzzling that it only gen-
erates a mild phenotype compared to that expected from
a complete lack of FGF signalling. We are aware of this
contradiction and currently do not have a proper answer
for it. The penetration of U0126 (5 hours after application
there was still pErk1/2 present as detected by our Western
blot analyses) could potentially also contribute the lack of
early FGF-inhibition-like phenotype.
It may also be possible that U0126 preferentially inhibits
only Mek1 or Mek2, a hypothesis that cannot be tested
due to lack of specific antibodies. Alternatively, some
aspect of FGF signaling may be transduced by the activity
of other molecules in addition to Mek1/2, and those par-
allel pathways are not inhibited by U0126.
U0126 might inhibit the regulatory processes involved in 
the secretion of PNBM components
U0126 treatment phenocopies 3 groups of mutants iden-
tified in earlier large-scale mutagenesis screens [62,63]:
the laminin, the coatomer complex (COPI) and the copper
transporter ATP7a  mutants [55,64,65]. They all have a
shortened body axis and an undulating NC in which the
chordamesoderm to mature NC transition process is
arrested with similar abnormal persistence of mRNAs of
structural and regulatory genes. Moreover, the structure of
the PNBM is also perturbed in these mutants.
laminin mutants (sleepy, grumpy and bashful), however, dif-
fer from U0126-treated embryos in several features. The
inner layer of the PNBM, consisting mostly of laminins
[51,52], is severely perturbed in these mutants, while in
U0126 treated embryos laminin distribution and
ultrastructure of the inner layer of the PNBM is entirely
normal. laminin mutants also have neural defects, while
neural development is normal in U0126 treated embryos.
In addition, U0126 treatments lead to other defects not
present in these mutants, such as the lack of pigmentation
and the presence of apoptosis between 48 and 72 hpf.
These results suggest that the role of Mek1/2 signaling in
NC differentiation is downstream of, or parallel to lam-
inin.
The COPI mutants (dopey, sneezy and happy [54]) and the
copper metabolism disrupting calamity mutant [55] very
closely resemble U0126-treated embryos with no addi-
tional or missing features. COPI is an essential part of the
mammalian secretory machinery [66,67] which partici-
pates in retrograde transport from Golgi to the ER. The
COPI complex comprised of 7 subunits and detailed
mechanism of its action during this process is still not
clear. It is very interesting to note however that according
to a recent paper, recruitment of the other coatomer com-
plex, COPII to ER export sites is regulated by phosphoryla-
tion via the p38/MAPK-pathway [68]. Due to the lack of
specific antibodies for phosphorylated and dephosphor-
ylated versions of the seven COPI subunits we could not
examine the possibility that Mek1/2 phosphorylation is
involved in regulation of this pathway but it is a promis-
ing direction for future research.
Interference with copper homeostasis phenocopies 
U0126-treatment in zebrafish embryos
The calamity zebrafish mutant (which bears a mutation on
the copper transporter gene ATP7a and can also be phen-
ocopied by copper chelating agents) [55,69] has a pheno-
type which is almost identical to that produced by U0126
treatment. Copper is an essential cofactor for the function
of a variety of enzymes involved in iron oxidation, pep-
tide amidation, cellular respiration and antioxidant
defense [70]. The copper transporter Atp7a is also affected
in Menkes disease in humans, which has skeletal defects
among its symptoms [71].
We can exclude the possibility of U0126 acting simply as
a copper chelator, since pretreatment of U0126 solution
with CuCl2 or CuSO4 did not prevent it from inducing NC
defects in the embryos (not shown). Still, our TEM results
demonstrate strong similarities between U0126-treated
embryos and embryos in which copper metabolism is
interfered with. These similarities include a milder
decrease in collagen mass and disorganized, shorter fibers
in the PNBM. This suggests that the copper metabolism
pathway or at least part of it is regulated by the U0126 tar-
get process, although the nature of this interaction is
unclear at present. Lysyl-oxidase is a copper dependent
amin-oxidase normally expressed in the NC, and involved
in the posttranslational, extracellular crosslinking of colla-
gens and elastin [72,73]. This enzyme is regulated by FGF
and Ras via the MAPK pathway and copper chelation
results in its inactivation. [74,75]. Recently, it has also
been shown that lysyl-oxidase activity regulates actin-fila-
ment formation, a process also affected in the NC ofBMC Developmental Biology 2008, 8:42 http://www.biomedcentral.com/1471-213X/8/42
Page 15 of 18
(page number not for citation purposes)
U0126-treated embryos [76]. Thus, the U0126 treatment
may inferfere with these processes directly or indirectly via
lysyl-oxidase activity and further studies will be necessary
to address this question.
Conclusion
In summary, using pharmacological inhibition of Mek1/2
we demonstrated that:
i. U0126 treatment causes a consistent phenotype includ-
ing lack of pigmentation and undulating NC which corre-
lates with lack of Erk1/2 phosphorylation in zebrafish
embryos.
ii. U0126 disrupts the NC differentiation process during
the chordamesoderm to mature NC transition step. As a
result, structural and signaling genes fail to be downregu-
lated during this process.
iii. U0126-treatment also leads to abnormal differentia-
tion and weakening of the PNBM. This leads to an inabil-
ity of the PNBM to support the NC against its own
hydrostatic pressure and results in undulations and bulges
in its structure.
iv. Using various methods of in vivo inhibition we
excluded FGF as the potential upstream signal in the NC
differentiation process affected by U0126.
There are 2 major questions arising from our experiments:
1. Is it possible that despite the overwhelming previously
published evidence proving its specificity (and our ERK
phosphorylation results) U0126 also might affect more
than just MEK1/2?
2. Is there a direct regulatory interaction between the
COPI-mediated retrograde transport, the copper-depend-
ent postranslational modifications by lysyl-oxidase and
the U0126-targeted pathway?
The answer to these questions might surface through the
cloning and identification of further uncharacterized
mutants with similar phenotypes (ie. crash test dummy,
leviathan). Alternatively, the identification of further path-
way-specific chemicals in large-scale pharmacological
screens which cause similar developmental defects could
help in elucidating this phenomenon.
Methods
Fish maintainance and MEK1/2-inhibitor treatments
Zebrafish (Danio rerio) were maintained under standard
conditions [77]. Embryos were collected from wild-type
(wik strain) crossings and kept at 28.5 C. Developmental
stages were identified based on [78]. U0126 (Promega,
V1121) was dissolved according to suppliers information
(10 mM in DMSO). Up to 50 embryos were treated in 12-
well plates with the appropriate concentration of U0126
diluted from stock in fish water. Embryos were kept in the
solution until fixation. 10 mM stock solutions of U0124
(Santa Cruz Biochemicals) and PD98059 (Calbiochem)
were made using DMSO. Embryos were treated as per
U0126 with the appropriate concentrations of the drug
(100 μM for U0124; 20, 25 and 30 μM for PD98059).
U0124 was dissolved in 2% DMSO fish water as it precip-
itated otherwise, the appropriate control was used to
ensure no effect of the high DMSO treatment.
In situ hybridizations, TUNEL stainings
Probe synthesis and whole mount in situ hybridizations
(WISH) were carried out as described previously [79]
using DIG labeling kit and NBT/BCIP developing solution
from LaRoche. Two-color WISH was done using DIG and
Fluorescein labelled probes recognized by the proper Fab
fragments linked to alkaline phosphatase enzymes. The
first probe was developed with NBT (La Roche) then fixed,
washed in PBST (PBS w. 0.1% Tween20), the antibody
destroyed in 0.2 M glycine solution washed again with
PBST, blocked and incubated with the anti-Fluorescein-
AP linked Fab fragment. After extensive washing this Ab
was developed using INT/BCIP solution (La Roche).
TUNEL stainings were carried out according to manufac-
turer's recommendation (Apoptaq kit, Chemicon)
Immunhistochemistry, Bodipy-ceramide, phalloidin-sytox 
stainings and microscopy
Standard procedures of whole mount immunhistochem-
istry were carried out using α-Acetylated tubulin Ab from
(Sigma; 1:1000), α-phospho-histone3 Ab (Upstate;
1:400) and α-laminin (Sigma; 1:400) α-pERK1/2 (Sigma;
1:250). In vivo Bodipy-ceramide stainings were done as
previously described [80]. Alexa568-conjugated phalloi-
din and Sytox-green (both Molecular Probes) stainings
were carried out on PFA-fixed embryos according to man-
ufacturers' protocols. All stained embryos were mounted
on a slide with a coverslip and photographed on a Leica
TCS2 confocal microscope.
For electron microscopy embryos were fixed in 2% para-
formaldehyde, 2% gluteraldehyde in 0.1 M sodium
cacodylate buffer (pH 7.3) with 2% CaCl2. Following
postfixation in cacodylate buffered 1% w/v osmium
tetraoxide (OsO4) (Johnson-Matthey) tissue was en bloc
stained in 2% w/v uranyl acetate and embedded in
medium Agar 100 epoxy resin (Agar Scientific). Ultrathin
sections (80–90 nm) contrasted with saturated uranyl ace-
tate solution and lead-citrate were examined and photo-
graphed using a JEOL1010 electron microscope.BMC Developmental Biology 2008, 8:42 http://www.biomedcentral.com/1471-213X/8/42
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SDS-PAGE/Western Blotting
Protein was extracted by homogenisation of deyolked
embryos, 7.5 μg of protein was seperated using 10% poly-
acrylamide gels, followed by transfer onto PVDF mem-
brane (Amersham). The pERK1/2 antibody was the same
as for immunohistochemistry applied here at 1:5000,
mouse anti-gamma tubulin (Sigma; 1:10,000) was the
loading control. Peroxidase activity from HRP-conjugated
secondaries (Sigma) was detected using an ECL detection
kit (Amersham).
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